Greater than 360 million persons will develop diabetes by the year 2030. New Insulins analogues, adjunctive non-insulin therapies such as use of incretin agents and SGLT-2 inhibitors are being actively pursued as a novel approach in diabetes therapy. Pluripotent stem cells in the production of pancreatic progenitor or insulin producing cells in also being researched towards the treatment of type 1 diabetes. Information technology has also enabled care providers enhance care process, and provide aid to diabetics .